Close Menu

NEW YORK – T2 Biosystems reported after the close of the market on Monday that its fourth quarter revenues rose 71 percent year over year.

For the three months ended Dec. 31, 2019, the company posted revenues of $3.1 million, lower than analysts' average estimate of $3.7 million. Product revenues were up 18 percent year over year at $1.6 million, and the firm's research revenues doubled to $1.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.